spondylarthropathy

spondylarthropathy (plural spondylarthropathies)

1. (medicine) Alternative spelling of spondyloarthropathy
   • 1993, Bulletin on the Rheumatic Diseases:

     They should be used in spondylarthropathy therapy only with great discretion. Sulfasalazine is beneficial occasionally, but usually is not well-tolerated.

   • 1998, Andrei Calin, Joel D. Taurog, The Spondylarthritides, Oxford University Press, USA:

     Moreover, patients with asymmetrical sacroiliitis in addition to, for example, a dactylitis or uveitis would be excluded from classification and yet clearly are part of the spondylarthropathy spectrum.

   • 2009, Richard Watts, Gavin Clunie, Frances Hall, Tarnya Marshall, Oxford Desk Reference: Rheumatology, Oxford University Press, USA, →ISBN, page 232:

     Spondylarthropathy (SpA) in children can exist as a discrete clinical entity (e.g. juvenile AS or arthritis associated with psoriasis or inflammatory bowel disease), but it is often not well differentiated.

   • 2010, Kewal K. Jain, The Handbook of Biomarkers, Springer Science & Business Media, →ISBN, page 131:

     Immunopathologic studies have suggested that the features of spondylarthropathy are distinctive, supporting a prominent role for innate immune cells, and can be consistently differentiated from rheumatoid arthritis.

   • 2010, Klaus Olgaard, Isidro B. Salusky, Justin Silver, The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease, OUP Oxford, →ISBN, page 272:

     The frequency of destructive spondylarthropathy increases with duration of survival. In patients treated for more than 10 years by hemodialysis, prevalence estimates vary according to centers between 12 and 48%.